HIGHBuilt-in & outside partyPipeline
verekitug
“10-K Item 1A: 'Verekitug is currently our only product candidate.'”
UPB · Concentration risk · 10-K extracted
Upstream Bio (UPB) concentration risks
Updated
The most significant concentration Upstream Bio discloses is verekitug, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Upstream Bio’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Upstream Bio's disclosed concentration is a single-asset pipeline dependency: verekitug is currently the company's only product candidate. This exposure is disclosed at a high share level, and the filing characterizes its character as mixed, reflecting that the risk has both a structural component — having one candidate is simply the current state of a clinical-stage biotech's pipeline — and an idiosyncratic component, since verekitug's own clinical, regulatory, and commercial outcomes will determine the company's fate. Because there is only this single disclosed exposure, it functions as the entirety of Upstream Bio's investment thesis rather than one risk among several. Unlike a company with multiple programs where a setback in one can be offset by progress in another, Upstream Bio has no other disclosed product candidate to diversify against a clinical trial failure, regulatory rejection, or commercial disappointment tied to verekitug. For investors, this means the stock's near-term and long-term value is essentially a direct bet on one molecule, and any material news about verekitug — positive or negative — should be expected to move the company's prospects in a highly correlated way, with no offsetting exposure disclosed elsewhere in the filing.
For the engine’s reasoning on UPB’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| UPB● | Upstream Bio, Inc. | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.